Hospital consultant chatting to administrator.

Your gateway to experimental cancer medicine

Our network is where cutting-edge research connects with patient care. We're accelerating innovation and trial delivery across the UK.

Why choose us?

A business woman chats to a doctor in a busy hospital corridor.

Our experimental cancer medicine centres 
(ECMC) network is a UK-wide collaboration of 
29 specialist cancer research centres.

Through this network of 17 adult and 12 paediatric centres, we offer unrivalled early-phase expertise and industry ready infrastructure.

We enable research innovation and bring first-in-human studies to patients by connecting the UK's best clinicians with industry and regulators.

Proven expertise, measurable impact

£150m

£150m invested in the network (since launch in 2007)

981

981 clinical trials in our portfolio (2022-2025)

9,000+

over 9,000 patients recruited (2022-2025)

What we do

Dark blue icon indicating the heads and shoulders of three people.

What we offer

We deliver early-phase trial infrastructure and expertise and streamlined access to an integrated adult and paediatric network.

Dark blue icon indicating a network with connected lines and dots.

What sets us apart

We provide a single entry point for feasibility and site engagement through a specialist UK-wide network, offer bespoke collaboration opportunities for industry, and maintain strong partnerships with UK regulators.

Dark blue icon showing two hands shaking.

How we deliver

We have recruited over 9,000 patients between 2022 and 2025, delivered global first-in-human and first-in-Europe studies, and provide access to a diverse, all-tumour, all-age patient population.

Who we work with

The ECMC network has supported efficient site identification and activation for multiple BioNTech early phase studies. Their partnership approach and proactive problem solving has delivered benefits to enrolment on individual studies, as well as system-wide implementation of national enablers to accelerate study start-up and delivery in the UK.

- Helen Galloway, Senior Director, Health Partnerships & Delivery, BioNTech